Following on from their recent partnership with Israel Biotech Fund (IBF), EPM caught up with Lonza's Pnina Weitz on the importance of early-stage support for emerging companies, and how robust strategies early on can pave a way to commercialisation.
Q. What impact are you hoping this collaboration agreement will have on biotech startups and innovative companies in Israel?
Lonza will provide Israel Biotech Fund’s portfolio companies with tailored advice, flexibility and services for the development and manufacturing of their biologics and small molecules. We hope to de-risk their drug development by equipping them with the manufacturing know-how and facilities and ultimately aim to enhance clinical and regulatory success to retain investor interest.